Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01507792
Other study ID # IRONCOUGH
Secondary ID
Status Completed
Phase N/A
First received December 29, 2011
Last updated January 8, 2012
Start date January 2002
Est. completion date January 2011

Study information

Verified date January 2012
Source University of Turin, Italy
Contact n/a
Is FDA regulated No
Health authority Italy: National Institute of Health
Study type Interventional

Clinical Trial Summary

Chronic cough is more frequent and severe in women than in men. Women often have decreased iron stores, due to menses and pregnancies. Aim of the study: to investigate if iron deficiency has a role in chronic cough by favouring airway hypersensitivity to inhaled irritants.


Description:

Women with chronic cough and iron deficiency, cough unresponsive to empiric treatment (suggested by cough guidelines) with antiH1-histaminic drug plus proton pump inhibitor.

Cough VAS (score from 1,best, to 5, worst). Histamine inhalation challenge, performed to assess bronchial, laryngeal, and cough thresholds, performed by delivering doubling concentrations, from 0.5 mg/ml up to 32 mg/ml, by a nebulizer. After each dose FEV1, as bronchial index, maximum mid-inspiratory flow (MIF50) as laryngeal index, and coughs number are assessed. Bronchial threshold is the concentration causing 20% decrease in FEV1, laryngeal threshold that causing 25% decrease in MIF50, cough threshold that causing 5 coughs. Histamine hyperresponsiveness of the bronchi (BHR), larynx (LHR) and cough (coughHR) are defined for thresholds equal or below 8 mg/ml.

Histamine thresholds and cough VAS obtained in baseline, after cough empiric treatment with antiH1-histaminic and proton pump inhibitor, and after iron supplementation.


Recruitment information / eligibility

Status Completed
Enrollment 22
Est. completion date January 2011
Est. primary completion date January 2011
Accepts healthy volunteers No
Gender Female
Age group 15 Years to 70 Years
Eligibility Inclusion Criteria:

- Unexplained cough : no detectable trigger for chronic cough identified, such as persistent rhinitis, chronic sinusitis, gastroesophageal reflux disease and asthma.

- no benefit by prior treatment with antiH1-histaminic drug and proton pump inhibitor.

- iron deficiency.

- normal lung function tests and chest radiography no relevant systemic disease.

- no acute respiratory infection in the last eight weeks.

- no pharmacological treatment in the last two weeks.

Exclusion Criteria:

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
iron sulphate
1 or 2 330 mg/daily iron sulphate oral tablets
antiH1-histamine, proton pump inhibitor
This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.

Locations

Country Name City State
Italy Respiratory Pathophysiology Clinic, ASO San Giovanni Battista Turin

Sponsors (2)

Lead Sponsor Collaborator
University of Turin, Italy Regione Piemonte

Country where clinical trial is conducted

Italy, 

References & Publications (2)

Bucca CB, Bugiani M, Culla B, Guida G, Heffler E, Mietta S, Moretto A, Rolla G, Brussino L. Chronic cough and irritable larynx. J Allergy Clin Immunol. 2011 Feb;127(2):412-9. doi: 10.1016/j.jaci.2010.10.038. Epub 2010 Dec 16. — View Citation

Bucca CB, Culla B, Guida G, Sciascia S, Bellone G, Moretto A, Heffler E, Bugiani M, Rolla G, Brussino L. Unexplained chronic cough and vitamin B-12 deficiency. Am J Clin Nutr. 2011 Mar;93(3):542-8. doi: 10.3945/ajcn.110.000802. Epub 2011 Jan 19. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Change in cough VAS Changes in cough VAS after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets)compared to the value observed after empiric treatment Cough VAS from 0 (best= no cough) to 5 (worst = severe cough) after 2 months empiric treatment and 2 months iron supplementation No
Primary Change in laryngeal histamine threshold Change in laryngeal threshold, assessed as the histamine concentration causing 25% decrease from baseline of MIF50 (PC25MIF50), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment after 2 months empiric treatment and 2 months iron supplementation No
Primary Change in cough histamine threshold Change in cough threshold, assessed as the histamine concentration causing 5 or more coughs(PC5cough), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment after 2 months empiric treatment and 2 months iron supplementation No
Secondary Change in bronchial histamine threshold Change in bronchial threshold, assessed as the histamine concentration causing 20% decrease from baseline of FEV1 (PC20FEV1), after 2 months iron supplementation (1 mg/kg elemental iron, corresponding to one or two 330 mg iron sulphate tablets), compared to the value obtained after empiric treatment after 2 months empiric treatment and 2 months iron supplementation No
See also
  Status Clinical Trial Phase
Completed NCT00116337 - Spinal Cord Stimulation to Restore Cough N/A
Not yet recruiting NCT04064333 - Slow-Stream Expiratory Muscle Strength Training for Veterans With Dysphagia Living in Long-term Care N/A
Recruiting NCT02482818 - Efficacy of Pregabalin on Chronic Cough Phase 1/Phase 2
Terminated NCT02269761 - Chest Ultrasound of ER Patients With Cough or SOB
Active, not recruiting NCT02065440 - The Effect of Ebastine/Pseudoephedrine on Subacute Cough N/A
Completed NCT01071161 - The Effect of Azithromycin in Patients With Chronic Obstructive Pulmonary Disease (COPD) and Chronic Productive Cough Phase 3
Completed NCT00353951 - An Observational Study of Cough / Lower Respiratory Tract Infection (LRTI) in Primary Care N/A
Terminated NCT00668317 - Bronchial Hyper-responsiveness in Reflux Cough Phase 3
Completed NCT00127686 - Effect of Honey and Dextromethorphan on Nocturnal Cough and Sleep Phase 1
Completed NCT00287339 - The Utility of Nexium in Chronic Cough and Reflux Disease Phase 4
Recruiting NCT05115097 - AI Evaluation of COVID-19 Sounds (AI-EChOS)
Recruiting NCT04457011 - Efficacy and Safety of Susu Zhike Granules for Treating Acute Cough Due to Common Cold With Cold-cough Syndrome in Children Phase 2
Recruiting NCT05042063 - Acoustic Cough Monitoring for the Management of Patients With Known Respiratory Disease
Recruiting NCT03922373 - A Study of Benzonatate Soft Capsule in Chinese Healthy Subjects Phase 1
Completed NCT05812209 - Stellate Ganglion Block to Treat Long COVID 19 Case Series
Recruiting NCT04767074 - A Non-pharmacological Cough Control Therapy N/A
Recruiting NCT05570539 - Assessment of the Pharmacokinetics of BLU-5937 Extended Release Prototypes and a BLU-5937 Immediate Release Reference Formulation Phase 1
Completed NCT03999203 - A Cross-sectional Study to Measure Cough in Severe Asthma N/A
Active, not recruiting NCT05479929 - Work of Breathing Assessment in Triage Scale
Recruiting NCT02495571 - Assessment of Voluntary and Reflex Cough in Patients With ALS N/A